Korean Market
EXCH
ORIENTBIO
★

ORIENTBIO Fails to Comply with Most Corporate Governance Core Indicators... Exposes Shareholder Return Deficiency and Governance Risks, Promises Future Improvements

 
EXCH
ORIENTBIO
★

FY2026 Individual Financial Statements: Operating Loss Widens, Net Loss Narrows

 
EXCH
ORIENTBIO
★

EGM Results: Stock Split and Articles Amendment Approved (99.9% Approval)